ALSO IN THIS MONTH'S ISSUE

• Democratic House Passes Rx Price Controls Amid Pandemic

  During this COVID-19 crisis, government should be collaborating closely with industry to promote innovation that will save lives, improve health and bring back prosperity that can come with safely reopening the economy. Yet, it is astonishing that House Democrats have chosen the opposite path.

• Leading And Managing Change During A Time Of Transition And Cultural Transformation

  While strategic leadership during times of transition and transformation can be especially challenging, consistently prioritizing organizational goals and strategies is paramount to success.

• Helping Managers Navigate Through The “New Normal”

  We determined that the skillset needed to lead change during this period of turbulence could be described as 3Cs: Calming – Creating – Connecting, and that each of the 3Cs would comprise a virtual training session.

• OTC Drug Monograph Reform In The CARES Act

  In March, Congress included in the CARES Act long-awaited reforms to the FDA regulation of OTC drugs. The changes are intended to address challenges with the old system, allowing for more nimble OTC oversight and potentially ushering in a new era of OTC safety and innovation.

• The Viral Startup

  ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.